• 

  Black Americans Have 2x the Alzheimer’s Risk—But They’re Underrepresented in Drug Trials
• 

  Testing for Racism: Here’s Why Alzheimer’s Tests Won’t Necessarily Work In Black Patients
• 

  Bill Sasse: An Insider’s Account of the Alzheimer’s Solanezumab Drug Trial
• 

  Alzheimer’s Drug Trial Process Has an Abysmal Failure Rate. VR Could Change That
• 

  Your Guide to FDA-Approved Alzheimer’s Drugs
• 

  Wegovy and Ozempic for Dementia in Clinical Trials at University of Oxford
• 

  Weight Loss Drug Wegovy’s Next Act: Treating Alzheimer’s?
• 

  Radicle’s Rethink of Clinical Trials: AI, Cell Phone Surveys, and Supplements Delivered to Your Door
• 

  Little-Known Cuban Alzheimer’s Drug Goes to Human Trials in Canada
• 

  Sneak Peek of Trial Data for Alzheimer’s Drug Donanemab
• 

  Dr. Emily Largent: Making Clinical Trials Better for Participants
• 

  Leqembi Clinical Trials Aren’t Over—Half of Participants Will Get the Drug for Free
• 

  Phil’s Journal: Another Alzheimer’s Drug, Lecanemab, Wins Early Approval—So, What Now?
• 

  Cuba Has an Experimental Alzheimer’s Drug In Human Trials
• 

  A New Kind of Alzheimer’s Drug, AD101, Makes Its Way

Previous345Next